Sanofi/Regeneron’s Libtayo hits the mark in first-line NSCLC
Positive data presented at the 2021 ESMO virtual congress
Read More
Tag: Libtayo
Sanofi and Regeneron’s Libtayo trial stops early due to survival improvement
Libtayo plus platinum-doublet chemotherapy led to a 29% reduction in risk of death compared to chemotherapy alone
Read More
Sanofi, Regeneron’s Libtayo cleared for basal cell carcinoma
Libtayo is the first immunotherapy indicated for patients with advanced basal cell carcinoma
Read More
US approval for Libtayo in advanced basal cell carcinoma
First immunotherapy indicated for certain BCC patients
Read More
Sanofi/Regeneron’s Libtayo shows benefit in BCC
BCC marks the second non-melanoma skin cancer for which Libtayo has demonstrated first-in-class data, the firms note
Read More
NICE approves CDF funding for Sanofi’s Libtayo
Around 560 patients per year with cutaneous squamous cell carcinoma are thought to be eligible for treatment with the drug in England
Read More
Libtayo bags EU approval for skin cancer
The European Commission has granted conditional marketing authorisation for the drug for patients who are not candidates for curative surgery or curative radiation.
Read More
US OKs Sanofi, Regeneron’s new skin cancer immunotherapy
Sanofi and Regeneron’s imunotherapy Libtayo has been cleared in the US to treat patients with certain forms of cutaneous squamous cell carcinoma (CSCC).
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
